What is the clinical evidence from this study?

Study design: Cohort. Population: Monoclonal Gammopathy of Undetermined Significance (MGUS) (n=1133). Intervention: Incidentally detected MGUS. Primary outcome: Progression from MGUS to multiple myeloma (MM).

What does this research mean for the field?

In a UK prospective cohort of 1,133 patients with incidentally detected Monoclonal Gammopathy of Undetermined Significance (MGUS), 10 participants have progressed to multiple myeloma during the baseline period. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To investigate the baseline characteristics and progression risks of MGUS in a UK cohort.

July 23, 2026Blood Cancer JournalOpen Access

SECURE study: baseline findings from a UK prospective cohort of incidentally detected MGUS

View Full Paper

Ask AI

Bookmark

Key result

Incidentally detected MGUS progresses to multiple myeloma in ~1% of patients in baseline cohort analysis.

n=1,133

Key Points

To investigate the baseline characteristics and progression risks of MGUS in a UK cohort.
Conducted a prospective cohort study in the UK
Focused on adults incidentally detected with MGUS
Analyzed progression endpoints based on MGUS subtypes
MGUS affects 5% of adults over 50, highlighting its prevalence in aging populations.
Progression risk to multiple myeloma averages ~1% annually, varying by MGUS subtype.
Different subtypes lead to distinct progression outcomes, with non-IgM MGUS primarily progressing to multiple myeloma.

Study Design

Type

Cohort (n=1,133)

Multicenter

Yes

PICO

Population

1,133 adults with incidentally detected monoclonal gammopathy of undetermined significance (MGUS) followed prospectively for up to 60 months.

Exposure / Comparator

Incidentally detected MGUS

Primary Outcome

Progression from MGUS to multiple myeloma (MM)

Limitations

Missing data expected under standard-of-care practice
Clinically detected cohort mostly from secondary care, not directly comparable with screened populations
Ethnicity and other subgroup analyses are currently underpowered
Short follow-up with few progression events
Lack of an MGUS-negative comparator group

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Early progression appears low in this MGUS cohort; leaves open optimal long-term surveillance and risk models.

Cite This Study

Knight et al. (2026) conducted a cohort in Monoclonal Gammopathy of Undetermined Significance (MGUS) (n=1,133). Incidentally detected MGUS was evaluated on Progression from MGUS to multiple myeloma (MM). In the baseline analysis of the UK SECURE prospective cohort of 1,133 patients with incidentally detected MGUS, 10 participants have progressed to multiple myeloma to date.

synapsesocial.com/papers/6a61ae6bfaa9903c51169c19 https://doi.org/10.1038/s41408-026-01576-x

View Full Paper

Ask AI

Bookmark